
# Title 21— FOOD AND DRUGS
### CHAPTER 9— FEDERAL FOOD, DRUG, AND COSMETIC ACT
#### § 360bbb–8. Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
##### (g) No delay in product review

(1) In general

Prior to a consultation with an external expert, as described in this section, relating to an investigational new drug application under section 355(i) of this title , a new drug application under section 355(b) of this title , or a biologics license application under section 262 of title 42 , the Director of the Center for Drug Evaluation and Research or the Director of the Center for Biologics Evaluation and Research (or appropriate Division Director), as appropriate, shall determine that

(A) such consultation will

(i) facilitate the Secretary’s ability to complete the Secretary’s review; and

(ii) address outstanding deficiencies in the application; or

(B) the sponsor authorized such consultation.

(2) Limitation

The requirements of this subsection shall apply only in instances where the consultation is undertaken solely under the authority of this section. The requirements of this subsection shall not apply to any consultation initiated under any other authority.
